Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

I had realized my own mortality. The fact of the matter was, I was going to die. And young. This was pre-Trikafta so the average life expectancy for someone with CF was approximately 44 years old. My ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

“In Phase 3 clinical trials, across a broad range of genotypes, once-daily ALYFTREK demonstrated non-inferiority to TRIKAFTA in ppFEV 1 response and statistically significant improvement in ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain Rating Scale after 12 weeks of treatment. Suzetrigine led to a statistically ...